SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2000 EMISPHERE TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 1-10615 13-3306985 -------- ------- ---------- (State or other (Commission (IRS Employer jurisdiction of File No.) Identification No.) incorporation) 765 Old Saw Mill River Road, Tarrytown, New York 10591 ------------------------------------------------ ----- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (914) 347-2220 Item 5. Other Events. ------------- On March 2, 2000, Emisphere Technologies, Inc. (the "Company") announced that Novartis Pharma AG ("Novartis") will extend its collaboration with Emisphere for the oral delivery of a second Novartis compound. The two companies will collaborate to select a second drug compound from several potential drug candidates. Attached as Exhibit 99.1 and incorporated herein by reference is the Company's press release, dated March 2, 2000. Item 7. Financial Statements and Exhibits. ---------------------------------- (c) Exhibits: Exhibit number Description of Exhibit -------------- ---------------------- 99.1 Press release dated March 2, 2000 Signatures ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: March 2, 2000 EMISPHERE TECHNOLOGIES, INC. /s/ Charles H. Abdalian ----------------------- Name: Chalres H. Abdalian, Jr. Title: Vice President, Chief Finaicial Officer and Secretary EXHIBIT INDEX Exhibit number Description of Exhibit - -------------- ---------------------- 99.1 Press Release dated March 2, 2000